Mark Evenstad founded and serves as CEO of ACOVA, Inc., a company dedicated to delivering better health outcomes for individuals living with chronic conditions. As CEO, Mark directs ACOVA’s long-term growth planning by building strong industry relationships and sourcing new business development opportunities that compliment and add value to the company’s offerings. Prior to founding ACOVA, Mark spent more than 15 years as CEO of Upsher-Smith Laboratories. Outside of work, Mark has contributed to his local community as a member of the Breck School Board of Trustees and Young Presidents Organization. Mark holds a B.A. in Business and an M.B.A. in Venture Management from the University of St. Thomas in St. Paul, MN.
As COO and CFO at ACOVA Inc., Chad Martinson oversees operating and financial strategy. Prior to joining ACOVA, Chad held a number of leadership roles in the fields of corporate finance, business unit finance, sales and marketing, and sales operations. Most recently, Chad served as Chief Financial Officer and Executive Vice President of Operations at Upsher-Smith Laboratories. He also previously served as Vice President of Finance and Business Development at Medtronic in the company’s neuromodulation division, and spent eight years at KPMG in the audit practice. He holds a B.A. in Accounting and Communications from Luther College in Decorah, Iowa, and an M.B.A. from Harvard Business School in Boston, Massachusetts.
Rusty Field serves as CEO of Upsher-Smith Laboratories, the U.S. subsidiary of Sawai Pharmaceutical Co, Ltd., a global generics pharmaceutical company. In his role as CEO of Upsher-Smith, Rusty drives the company’s direction and operating performance. His primary responsibilities involve managing corporate operations, developing business strategy, expanding the company’s portfolio of products and programs, and delivering revenue and profitability to meet the company’s growth and future success objectives. Rusty joined Upsher-Smith in 2014 after five years with United Healthcare, where he was responsible for distribution strategy and channel development. Before that, he spent twenty years with Ameriprise Financial, where he held senior executive sales, marketing and general management positions. Rusty holds a B.A. in Economics from Williams College in Williamstown, Massachusetts.
Dr. William Pullman
As President of Proximagen, an early clinical stage drug development company, Dr. William (Bill) Pullman oversees the company’s strategic direction and scientific affairs, including pipeline selection and development, and all clinical, medical, and regulatory operations. Before joining Proximagen, Bill served as Chief Scientific Officer of Upsher-Smith Laboratories. He also formerly held positions as Chief Research and Development Officer and Chief Development Officer at Dyax Corp., Chief Medical Officer at Cubist Pharmaceuticals, and Senior Vice President, Exploratory Development at TransForm Pharmaceuticals. Bill completed his primary medical training at the University of Western Australia and is a fellow of the Royal Australian College of Physicians. He also received a Ph.D. in Medicine and Clinical Science (Immunology) from the Australian National University.
As Chief Executive Officer of Pairnomix, Matthew Fox is responsible for overseeing the company’s operations, developing the growth strategy, and delivering revenue and profitability. Prior to joining Pairnomix, Matthew served as Senior Vice President of Corporate Strategy at Upsher-Smith Laboratories, where he led business intelligence efforts, developed and maintained trade and advocacy partnerships, and sourced new opportunities to expand and grow the business. Prior to that role, Matthew served as a Portfolio Manager at Bank am Bellevue in Zurich, Switzerland, investing in global biotechnology and pharmaceutical companies. He holds a B.A. in Neuroscience and Behavior from Wesleyan University in Middletown, Connecticut.